2009 Faculty Publications

Al-Lozi

  1. Lopate,G.; Baloh,R.H.; Al-Lozi,M.T.; Miller,T.M.; Filho,J.A.; Ni,O.; Leston,A.; Florence,J.; Schierbecker,J.; Allred,P. Familial ALS with extreme phenotypic variability due to the I113T SOD1 mutation. Amyotroph.Lateral.Scler. 2009:1-5

Ances

  1. Ances, B. M., Bhatt A., Vaida, F., Alexander, T., Rosario, D., Marquie-Beck, J., Ellis, R.J., Letendre, S., Grant, I., McCutchan, J.A., HNRC. (2009) Role of Metabolic Syndrome Risk Factors in HIV-Associated Stroke. Journal of Neurovirology. 15(3):249-256.
  2. Letendre, S., Ellis, R.J., Everall,, I., Ances, B. M., Bhatri, A., McCutchan, J.A. Neurologic Complications of HIV Disease and Their Treatment. Topics in HIV Medicine. 17(2):46-56.
  3. Ances, B. M., Sisti, D., Vaida, F., Liang, C.L., Leontiev, L., Perthen, J.L., Buxton, R.B., Benson, D.A., Smith D.A., Little, S.J., Richman, D.D., Moore, D.J., Ellis, R.J. (2009) Resting Cerebral Blood Flow: A Potential Biomarker of the Effects of HIV in the Brain. Neurology. 73(9):702-8.
  4. Ances, B. M., Vaida, F., Rosario, D., Marquie-Beck, J., Ellis, R.J., Simpson, D.M., Clifford, D.B., McArthur, J.C., Grant, I., McCutchan, J.A. (2009) Role of Metabolic Syndrome Components in HIV Associated Sensory Neuropathy. AIDS. 23(17):2317-22

Baloh

  1. Fuentealba RA, Udan M, Bell S, Wegorzewska I, Shao J, Diamond MI, Weihl CC, Baloh RH. Interaction with polyglutamine aggregates reveals a Q/N rich domain in TDP-43. J Biol Chem. 2010 June 16th
  2. Misko A, Jiang S, Wegorzewska I, Milbrandt J, Baloh RH. Mitofusin 2 is necessary for transport of axonal mitochondria and interacts with the Miro/Milton complex. J Neurosci, 2010 Mar 24;30(12):4232-40.
  3. Wegorzewska I, Bell S, Cairns N, Miller T, Baloh RH. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Nat Acad Sci. 2009, Nov 3;106(44):18809-14.
  4. Baloh RH, Schmidt RE, Pestronk A, Milbrandt J (2007). Altered axonal mitochondrial transport in the pathogenesis of Charcot-Marie-Tooth disease from mitofusin 2 mutations. J Neurosci 27, 422-430.
  5. Baloh RH, Salavaggione E, Milbrandt J, Pestronk A (2007) Familial parkinsonism and ophthalmoplegia from a mutation in the mitochondrial DNA helicase twinkle. Arch Neurol. Jul;64(7):998-1000
  6. Baloh RH, Rakowicz W, Gardner R, Pestronk A (2007) Frequent atrophic groups with mixed-type myofibers is distinctive to motor neuron syndromes. Muscle Nerve. Jul;36(1):107-10.
  7. Baloh RH, Enomoto H, Johnson EM Jr, and Milbrandt J. (2000). The GDNF family ligands and receptors – implications for neural development. Curr. Opin Neurobiol. 10, 103-110
  8. Baloh RH, Tansey MG, Lampe PA, Fahrner TJ, Enomoto H, Simburger K, Leitner ML, Araki T, Johnson EM Jr, and Milbrandt J. (1998). Artemin, a novel member of the GDNF ligand family supports peripheral and central neurons and signals through the GFRa3-RET receptor complex. Neuron 21, 1291-1302.

Bateman

  1. Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC, Yarasheski KE, Friedrich SW, DeMattos RB, May PC, Paul SM, Holtzman DM. A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Annals of Neurology 2009;66:48-54.
  2. Wildsmith KR, Han B, Bateman RJ. Method for the simultaneous quantitation of apolipoprotein E isoforms using tandem mass spectrometry. Analytical Biochemistry 2009;395:116-8.
  3. Kang J-E, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, Fujiki N, Nishino S, Holtzman DM. Amyloid-Aβ Dynamics Are Regulated by Orexin and the Sleep-Wake Cycle. Science 2009;326:1005-7.

Brunstrom-Hernandez

  1. Wingert JR, Burton H, Sinclair RJ, Brunstrom JE, Damiano DL: Joint-position sense and kinesthesia in cerebral palsy. (In Press), Arch Phys Med Research.

Cairns

  1. VCP Mutations Causing Frontotemporal Lobar Degeneration Disrupt Localization of TDP-43 and Induce Cell Death.
    Gitcho MA, Strider J, Carter D, Taylor-Reinwald L, Forman MS, Goate AM, Cairns NJ.J Biol Chem. 2009 May 1;284(18):12384-98. Epub 2009 Feb 23. PMID: 19237541 [PubMed – in process]
  2. Ubiquitin associated protein 1 is a risk factor for frontotemporal lobar degeneration. Rollinson S, Rizzu P, Sikkink S, Baker M, Halliwell N, Snowden J, Traynor BJ, Ruano D, Cairns N, Rohrer JD, Mead S, Collinge J, Rossor M, Akay E, Guerreiro R, Rademakers R, Morrison KE, Pastor P, Alonso E, Martinez-Lage P, Graff-Radford N, Neary D, Heutink P, Mann DM, Van Swieten J, Pickering-Brown SM.
    Neurobiol Aging. 2009 Apr;30(4):656-65. Epub 2009 Feb 12.
    PMID: 19217189 [PubMed – in process]
  3. Hippocampal pathology in progressive supranuclear palsy (PSP): a quantitative study of 8 cases. Armstrong RA, Lantos PL, Cairns NJ.
    Clin Neuropathol. 2009 Jan-Feb;28(1):46-53. PMID: 19216220 [PubMed – indexed for MEDLINE]
  4. A quantitative study of the pathological changes in the cerebellum in 15 cases of variant Creutzfeldt-Jakob disease (vCJD). Armstrong RA, Ironside JW, Lantos PL, Cairns NJ. Neuropathol Appl Neurobiol. 2009 Feb;35(1):36-45. PMID: 19187059 [PubMed – indexed for MEDLINE]
  5. Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations.
    Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, Kovacs GG, Ghetti B, Halliday G, Holm IE, Ince PG, Kamphorst W, Revesz T, Rozemuller AJ, Kumar-Singh S, Akiyama H, Baborie A, Spina S, Dickson DW, Trojanowski JQ, Mann DM.
    Acta Neuropathol. 2009 Jan;117(1):15-8. Epub 2008 Nov 18. No abstract available.
    PMID: 19015862 [PubMed – indexed for MEDLINE]

Clifford

  1. Best BM, Letendre SL, Brigid E, Clifford DB, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Simpson DM, Ellis R, Capparelli EV, Grant I for the CHARTER Group. Low atazanavir concentrations in cerebrospinal fluid. AIDS 2009; 23:83-7.
  2. Sacktor N, Nakasujja N, Skolasky RL, Robertson K, Musisi S, Ronald A, Katabira E, Clifford DB. Benefits and risks of stavudine therapy for HIV-associated neurologic complications in Uganda. Neurology 2009; 72:165-170.
  3. Wenning W, Haghikia A, Laubenberger J, Clifford DB, Behrens PF, Chan A, Gold R. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. NEJM 2009; 361:1075-1080.
  4. Marra CM, Zhao Y, Clifford DB, Letendre S, Evans S, Henry K, Ellis RJ, Rodriguez B, Coombs RW, Schifitto G, McArthur JC, Robertson K. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 2009; 2009; 23:1359-66.
  5. Sacktor N, Nakasujja N, Skolasky RL, Rezapour M, Robertson K, Musisi S, Katabira E, Ronald A, Clifford DB, Laevendecker O, and Quinn T. HIV subtype D is associated with dementia compared to subtype A, in immunosuppressed individuals at risk for cognitive impairment in Kampala, Uganda. Clin Inf Dis, 2009; 49:780-786.
  6. Valcour V, Yeh TM, Bartt R, Clifford D, Gerschenson M, Evans SR, Cohen BA, Ebenezer GJ, Hauer P, Millar L, Gould M, Tran P, Shikuma C, Souza S, McArthur JC, AIDS Clinical Trials Group (ACTG) 5157 Protocol Team. Acetyl-L-carnitine and nucleoside reverse transcriptase inhibitor-associated neuropathy in HIV infection. HIV Medicine 2009; 10:103-110.
  7. Clifford DB, Smurzynski M, Park LS, Yeh TM, Zhao Y, Blair L, Arens M, Evans SR. Effects of active HCV replication on neurologic status in HIV RNA virally suppressed patients. Neurology 2009; 73:309-314.
  8. Boero J, Duntley J, Clifford D, Ding J, Shannon W. Actigraphy and functional data analysis for objective measurement of fatigue: a case study in HIV/AIDS. JSM Proceedings 2009; in press.
  9. Marzocchetti A, Tompkins T, Clifford DB, Gandhi RT, Kesari S, Berger JR, Simpson DM, Prosperi M, De Luca A, Koralnik IJ. Determinants of survival in progressive multifocal leukoencephalopathy. Neurology 2009; 73:1551-1558.
  10. Joseph J, Clifford D, Douglas SD, Fox H, Gendelman HE, Gonzalez-Scarano F, Grant I, Major E, McArthur J, NeuroAIDS Research Participants. Planning future strategies for domestic and international NeuroAIDS Research, July 24-25, 2008. J Neuroimmune Pharmacol 2009; 4:283-297. (PMCID: 27197353)
  11. Tornatore C, Clifford DB. Clinical vigilance for progressive multifocal leukoencephalopathy in the context of natalizumab use. Multiple Sclerosis 2009; 15:S16-S25.
  12. Clifford DB, Fagan AM, Holtzman DM, Morris JC, Teshome M, Shah AR, Kauwe JSK. CSF biomarkers of Alzheimer disease in HIV-associated neurologic disease. Neurology 2009; 73:1982-1987.
  13. Clifford DB, DeLuca A, Simpson DM, Arendt G, Giovannoni G, Nath A. Natalizumab associated progressive multifocal leukoencephalopathy: Lessons from early cases. Lancet Neurology 2009; submitted.
  14. Ances BM, Christensen JJ, Teshome M, Taylor J, Xiong C, Aldea P, Fagan AM, Holtzman DM, Morris JC, Mintun MA, Clifford DB. Unimpaired HIV+ Participants Do Not Have Increased 11C-PIB: A Case Control Study. Neurology 2009; submitted.
  15. Ances BM, Vaida F, Rosario D, Marquie-Beck J, Ellis RJ, Simpson DM, Clifford DB, McArthur JC, Grant I, McCutchan JA, CNS HIV Antiretroviral Therapy Effects Research (CHARTER) Metabolic Study Group. Role of metabolic syndrome components in HIV-associated sensory neuropathy. AIDS 2009; 23:2317-22. (PMID: 19823068)
  16. Margulies S, Hicks R. Combination therapies for traumatic brain injury; prospective considerations. J Neurotrauma 2009; 26:925-39.

Coats

  1. Malmstrom TK, Miller DK, Coats MA, Jackson P, Miller JP, Morris JC. Informant based dementia screening in a population-based sample of African Americans. ADAD 2009; 23:117-123. (NIHMSID: NIHMS127287)
  2. Galvin JE, Meuser TM, Coats MA, Bakal DA, Morris JC. The “Portable” CDR: Translating the clinical dementia rating interview into a PDA format. Alzheimer Dis Assoc Disord 2009; 23:44-49..

Corbetta

  1. Shulman GL, Astafiev SV, Franke D, Pope DL, Snyder AZ, McAvoy MP, Corbetta M. Interaction of stimulus-driven reorienting and expectation in ventral and dorsal frontoparietal and basal ganglia-cortical networks. Journal of Neuroscience (2009) Apr 8;29(14):4392-407.
  2. Sylvester C.M., Shulman G.L., Jack A.I., Corbetta M. Anticipatory and stimulus-evoked BOLD modulations related to spatial attention reflect a common additive signal. Journal of Neuroscience 2009 Aug 26; 29(34):10671-82.
  3. Lewis C.M., Baldassarre A., Committeri G., Romani G.L., Corbetta M. Learning Sculpts the Spontaneous Activity of the Resting Human Brain. Proceedings National Academy of Science U S A (2009) Oct 13;106 (41):17558-63.
  4. Rengachary, J. d’Avossa G., Sapir A., Shulman G.L., Corbetta, M. Is the Posner reaction time test more accurate than clinical tests in detecting left neglect in acute and chronic stroke? Archives of Physical Medicine and Rehabilitation 2009 (in press)
  5. Deco G. & Corbetta M The Dynamic Balance of the Brain at Rest The Neuroscientist (in press)
  6. Carter, A., Astafiev, S. Lang, C., Connor, L. Struna, J. Strube, M. Pope, D. Shulman, G. Corbetta, M. Resting Inter-hemispheric fMRI Connectivity Predicts Performance after Stroke Annals of Neurology (in press)
  7. de Pasquale F., Della Penna S., Snyder A.Z., Mantini D., Marzetti L., Lewis C.M., Belardinelli P., Ciancetta L., Pizzella V., Romani G.L. and Corbetta M. Temporal dynamics of spontaneous MEG activity in brain networks. Proceedings National Academy of Science U S A (in revision)
  8. Patel G.H., Shulman G.L., Baker J.T., Akbudak E., Snyder A.Z., Snyder L.H., and Corbetta M. Topographic Organization of Macaque Area LIP, Proceedings National Academy of Science U S A (in revision)
  9. Shulman G.L., Pope D.L.W. Astafiev S.V., McAvoy M.P., Snyder A.Z. and Corbetta M. Right hemisphere dominance for spatial selective attention and target detection occurs outside the dorsal fronto-parietal network. Journal of Neuroscience (in revision)
  10. Astafiev S.V., Snyder A.Z., Shulman G.L., and Corbetta M. Comment on “Modafinil shifts human locus coeruleus to low-tonic, high-phasic activity during functional MRI” and “Homeostatic sleep pressure and responses to sustained attention in the suprachiasmatic area”. Science (in revision)
  11. Sestieri C., Shulman G.L. and Corbetta M. Attention to memory and the environment: functional specialization and dynamic competition in human posterior parietal cortex Journal of Neuroscience (submitted)
  12. Mantini M., Della Penna S., Marzetti, L., de Pasquale, F., Pizzella V., Corbetta M. and Romani GL Functional electromagnetic imaging for the high-resolution spatio-temporal analysis of neuronal activity. Neuroimage (submitted)

Criswell

  1. Racette BA, Good LM, Kissel AM, Criswell SR, Perlmutter JS. A population-based study of parkinsonism in an Amish community. Neuroepidemiology 2009; 33(3):225-30.
  2. Willis AW, Evanoff BA, Lian M, Criswell SR, Racette BA. Geographic and Ethnic Variation in Parkinson Disease: A Population-Based Study of US Medicare Beneficiaries. Neuroepidemiology. Accepted for publication 10/14/2009.
  3. Criswell SR, Sterling C, Swisher L, Evanoff BA, Racette BA. Sensitivity and specificity of the finger tapping task for the detection of psychogenic movement disorders. Parkinsonsim and Related Disorders. Accepted for publication 11/16/2009.

Cross

  1. De Jager P, et al. Meta-analysis of genome scans and replication identify CD6, ICSBP1, and TNFRSF1A as novel multiple sclerosis susceptibility loci. Nature Genetics (in press)
  2. Naismith RT, Tutlam N, Xu J, Klawiter EC, Shepherd, JB, Song, SK, Cross AH. Optical Coherence Tomography is Less Sensitive than Visual Evoked Potentials in Optic Neuritis Neurology 2009 (in press)Naismith RT, Xu J, Tutlam NT, Snyder A, Benzinger T, Shimony J, Shepherd JB, Trinkaus K, Cross AH, Song SK: Quantification of optic neuritis using directional diffusivities derived from diffusion tensor imaging. Neurology 2009; 72: 589-94.
  3. Budde MD, Xie M, Cross AH, Song SK: Axial diffusivity is the primary correlate of axonal injury in the EAE spinal cord: A quantitative pixelwise correlation analysis. J Neuroscience 2009; 29: 2805-2813.
  4. Naismith RT, Tutlam NT, Xu J, Klawiter EC, Shepherd JB, Trinkaus K, Song SK, Cross AH. Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis. Neurology 2009; 72: 1077-1082
  5. Klawiter EC, Alvarez E, Xu J, Paciorkowski AR, Zhu L, Parks BJ, Cross AH, Naismith RT. NMO-IgG Detected in CSF in Seronegative Neuromyelitis Optica. Neurology 2009; 72: 1101-1103
  6. Fenoglio C, Scalabrini D, Piccio L, deRiz M, Venturelli E, Cortini F, Villa C, Serpente M, Parks BJ, Rinker J, Bresolin N, Cross AH, Scarpini E, Galimberti D. Candidate gene analysis of selectin gene cluster in patients with multiple sclerosis J. Neurology 2009 (in press)

Dhar

  1. Murphy T, Dhar R, Diringer MN. Conivaptan bolus dosing for the correction of hyponatremia in the neurointensive care unit. Neurocrit Care 2009; 11(1): 14-19.
  2. Dhar R, Zazulia AR, Videen TO, Zipfel GJ, Derdeyn CP, Diringer MN. Red blood cell transfusion increases cerebral oxygen delivery in patients with anemia after subarachnoid hemorrhage. Stroke 2009; 40: 3039-44.
  3. Sampson T, Dhar R, Diringer MN. Factors associated with the development of anemia after subarachnoid hemorrhage. Neurocrit Care 2009, DOI: 10.1007/s12028-009-9273-1
  4. Dhar R. Neuromuscular respiratory failure. In: Continuum – Critical Care Neurology. Diringer MN, Ed. AAN 2009.
  5. Dhar R. To clip or coil ruptured cerebral aneurysms? That is the question. In: American Academy of Neurology 2009 Meeting Syllabus.
  6. Dhar R, Diringer MN. Neurocritical care. In: Neurology – . An Evidence-Based Approach. Burneo J, Demaershalk B, Jenkins ME. Eds. Springer: 2009.
  7. Dhar R, Zazulia AR, Videen T, Diringer MN. Red blood cell transfusion increases cerebral oxygen delivery after subarachnoid hemorrhage [Oral Platform; Best Scientific Abstract Award]. Presented at: Neurocritical Care Society Annual Meeting, October 2008.
  8. Diringer M, Zazulia A, Dhar R, Videen T, Derdeyn C. Impact of induced hypertension on cerebral oxygen delivery in subarachnoid haemorrhage [Oral Platform; Best Scientific Abstract Award]. Presented at: Neurocritical Care Society Annual Meeting, November 2009.
  9. Human T, Dhar R. A bolus of conivaptan lowers intracranial pressure in a patient with hyponatremia after traumatic brain injury [Poster]. Presented at: Neurocritical Care Society Annual Meeting, November 2009.
  10. Sampson T, Dhar R, Zipfel GJ. Seizure-induced exacerbation of delayed cerebral ischemia [Poster]. Presented at Neurocritical Care Society Annual Meeting, November 2009.
  11. Corry JJ, Diringer MN, Abdelhak T, Dhar R, Varelas P. Hypothermia for refractory status epilepticus [Big Idea Session]. Presented at: Neurocritical Care Society Annual Meeting, November 2009.

Diringer

  1. Diringer MN, Management of aneurysmal subarachnoid hemorrhage: a concise definitive review, Crit Care Med, 2009 Feb;37(2):432-40

Dodson

  1. Gurnett CA, and Dodson WE. Definitions and classification of epilepsy. In The Treatment of Epilepsy. Edited by Simon Shorvon, David Fish, Jerome Engel. Blackwell Publishing, Limited, Oxford (in press 2008).

Duntley

  1. Weinstock LB, Walters A, Duntley S, Zeiss S, Lewis N. Antibiotic therapy improves restless legs syndrome: a double-blind, controlled study of short course of rifaximin. Sleep Medicine 2009; 10(S2):S28.
  2. Laurent Seugnet, Yasuko Suzuki, Matthew Thimgan, Jeff Donlea, Sarah Israel, Steve Duntley, and Paul Shaw “Identifying sleep regulatory genes using a Drosophila model of insomnia”. J Neurosci, 2009 June 3;29(22):7148-57.
  3. Finkel KJ, Searleman AC, Tymkew H, Tanaka CY, Saager L, Safer-Zadeh E, Bottros M, Selvidge JA, Jacobsohn E, Pulley D, Duntley S, Becker C, Avidan MS. Prevalence of undiagnosed obstructive sleep apnea among adult surgical patients in an academic medical center. Sleep Med. 2009 Jan 29. [Epub ahead of print]

Eisenman

  1. Anderson NR, Wisneski K, Eisenman L, Moran DW, Leuthardt EC, Krusienski DJ. An offline evaluation of the autoregressive spectrum for electrocorticography. IEEE Trans Biomed Eng. 2009;56(3):913-6.
  2. Eisenman LN, Shu HJ, Wang C, Aizenman E, Covey DF, Zorumski CF, Mennerick S. NMDA potentiation by visible light in the presence of a fluorescent neurosteroid analogue. J Physiol. 2009;587(Pt 12):2937-47.
  3. Shu HJ, Eisenman LN, Wang C, Bandyopadhyaya AK, Krishnan K, Taylor A, Benz AM, Manion B, Evers AS, Covey DF, Zorumski CF, Mennerick S. Photodynamic effects of steroid conjugated fluorophores on GABAA receptors. Mol. Pharm. 2009;76:754-65.
  4. Chisari M, Eisenman LN, Krishnan K, Bandyopadhyaya AK, Wang C, Taylor A, Benz A, Covey DF, Zorumski CF, Mennerick S. The influence of neuroactive steroid lipophilicity on GABAA receptor modulation: evidence for a low affinity interaction. J Neurophysiol. 2009;102:1254-64.
  5. Kress GJ, Dowling M, Eisenman LN, Mennerick S. The role of sodium channel clustering in the depolarized action potential threshold of dentate granule neurons. Hippocampus. In Press.
  6. Mennerick SM, Chisari M, Shu HJ, Taylor A, Vasek M, Eisenman LN, Zorumski CF. Diverse voltage-sensitive dyes modulate GABAA receptor function. J Neurosci. In Press.

Fagan

  1. Fagan AM, Head, D, Shah AR, Marcus D, Mintun M, Morris JC, Holtzman DM. Decreased cerebrospinal fluid Aβ42 correlates with brain atrophy in cognitively normal elderly. Ann Neurol 2009, 65:176-183. PMCID: PMC2763631
  2. Okereke OI, Xia W, Irizarry MC, Sun X, Qiu WQ, Fagan AM, Mehta PD, Hyman BT, Selkoe DJ, Grodstein F. Performance characteristics of plasma amyloid-beta 40 and 42 assays. J Alzheimers Dis., 2009,16:277-85. PMCID: PMC2737811
  3. Kauwe JS, Wang J, Mayo K, Morris JC, Fagan AM, Holtzman DM, Goate AM. Alzheimer’s disease risk variants show association with cerebrospinal fluid amyloid beta. Neurogenetics. 2009,10:13-7. PMCID: PMC2726757
  4. Craig-Schapiro R, Fagan AM, Holtzman DM. Biomarkers of Alzheimer’s disease. Neurobiol Dis., 2009, 35:128-40. PMCID: PMC2747727
  5. Snider BJ, Fagan AM, Roe CM, Shah AR, Grant EA, Xiong C, Morris JC, Holtzman DM Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer’s type. Arch Neurol, 2009, 66:638-45. PMCID: PMC2759394
  6. Britschgi M, Olin CO, Johns HT, Takeda-Uchimura Y, LeMieux M, Rufibach K, Rajadas J, Zhang H, Tomooka B, Robinson WH, Clark CM, Fagan AM, Galasko DG, Holtzman DM, Jutel M, Kaye JA, Lemere CA, Leszek J, Li G, Peskind ER, Quinn JF, Yesavage JA, Ghiso J., and Wyss-Coray T. Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer’s disease. PNAS, 2009, 106:12145-50. PMCID: PMC2715538
  7. Clifford DB, Fagan AM, Holtzman DM, Morris, JC, Teshome M, Shah AR, Kauwe JSK. CSF biomarkers of Alzheimer’s Disease in HIV associated neurological disease. Neurology, 2009, 73:1982-87. PMCID: PMC2790234
  8. Duchek JM, Balota DA, Tse CS, Holtzman DM, Fagan AM, Goate AM. The utility of intraindividual variability in selective attention tasks as an early marker for Alzheimer’s disease. Neuropsychology, 2009, 23:746-58. PMCID: PMC2779520
  9. Morris JC, Roe CM, Xiong C, Fagan AM, Goate Am, Holtzman DM, Mintun MA. APOE predicts Aβ but not tau Alzheimer’s pathology in cognitively normal aging, Ann Neurol, 2009, in press.
  10. Cairns NJ, Ikonomovic MD, Benzinger T, Storandt M, Fagan AM, Shah AR, Taylor-Reinwald L, Carter D, Felton A, Holtzman DM, Mintun MA, Klunk WE, Morris JC. Absence of Pittsburgh Compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease, Arch Neurol, 2009, 66:1557-62. NIHMSID: 152224
  11. Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, Fagan AM, Holtzman DM, Mintun MA. PIB imaging predicts progression from cognitively normal to symptomatic Alzheimer’s disease, Arch Neurol, 2009, 66:1469-75. NIHMSID: 153035
  12. Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer’s disease, Nature, 2009, 461:916-22 NIHMS 169707 [PMC Journal – in process]
  13. Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, Mach RH, Marcus D, Morris JC, Holtzman DM. Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer’s disease. EMBO Mol Med, 2009, 1:371-80. NIHMSID: 167617
  14. Hinrichs AL, Mintun MA, Head D, Fagan AM, Holtzman DM, Morris JC, Goate AM. Cortical binding of Pittsburgh Compound B, an endophenotype for genetic studies of Alzheimer’s disease. Biol. Psychiatry, 2009, in press. NIHMSID: 171962

Ford

  1. Zipfel GJ, Han H, Ford AL, and Lee JM. Cerebral amyloid angiopathy: progressive disruption of the neuro-vascular unit. Stroke. 2009;40:S16-19.
  2. Ford AL, Connor LT, Tan DK, Williams JA, Lee JM, and Nassief AM. Resident-based acute stroke protocol is expeditious and safe. Stroke. 2009; 40(4):1512-4.

Fucetola

  1. Fucetola, R., Connor, L. T., Strube, M. J., and Corbetta, M. (2009). Unraveling nonverbal cognitive performance in acquired aphasia. Aphasiology, 23(12), 1418-1426.
  2. Fucetola, R. (2009, October). Evidence-based treatment of post-stroke aphasia. Presented at the Rehabilitation Research Day: Update on Stroke Recovery and Rehabilitation, St. Louis.

Galvin

  1. Seugnet L, Galvin JE, Suzuki Y, Vine L, Shaw PJ. Persistent short-term memory defects following sleep deprivation in a Drosophila model of Parkinson’s disease. Sleep, In Press 2009.
  2. Johnson DK, Storandt M, Morris JC, Galvin JE. Longitudinal study of the transition from healthy aging to Alzheimer disease. Arch Neurol In Press, 2009.
  3. Galvin JE. When a tremor is not just a tremor: Cognitive and functional decline in Essential Tremor, a more complex disorder that we thought. J Am Med Dir Assoc In Press 2009.
  4. Norton JB, Cairns N, Galvin JE, Goate A. Presenilin 1 g217r mutation linked to alzheimer¹s disease with cotton wool plaques. Neurology In Press 2009
  5. Galvin JE, Meuser TM, Boise L, Connell CM. Determinants of physician referral for patient recruitment to Alzheimer disease clinical trials. Alz Dis Assoc Disord, In Press, 2009
  6. Galvin JE, Meuser TM, Coats MA, Bakal DA, Morris JC. The portable CDR: Translating the Clinical Dementia Rating interview into a PDA format. Alz Dis Assoc Disord 23:44-49, 2009

Gurnett

  1. Gurnett CA, Alaee F, Desruisseau D, Boehm S, Dobbs MB. Skeletal muscle contractile gene (TNNT3, MYH3, TPM2) mutations not found in vertical talus or clubfoot, Clin Orthop Relat Res, 2009; 467(5):1195-200.
  2. Gurnett CA, Alaee F, Bowcock AM, Kruse L, Lenke LG, Bridwell KH, Kukio T, Luhmann SJ, Dobbs MB, Genetic linkage localizes the adolescent idiopathic scoliosis and pectus excavatum gene to chromosome 18q, Spine, 2009, 34(2):E94-100.
  3. Gurnett CA, Alaee F, Bick J, Gomez-Silvero N, Dobbs MB. Skeletal muscle contractile gene (TNNT3, MYH3, and TPM2) mutations are not found in familial vertical talus and congenital clubfoot, Clin Orthop Relat Res, 2009, Feb 18.
  4. Kruse L, Gurnett CA, Hootnick D, Dobbs MB. Magnetic resonance angiography in clubfoot and vertical talus: a feasibility study, Clin Orthop Relat Res, 2009, Jan 6.

Hogan

  1. Hogan RE, Bouilleret V, Liu YR, Wang L, Williams JP, Jupp B, Myers D, O’Brien TJ. MRI-based large deformation high dimensional mapping of the hippocampus in rats: development and validation of the technique. Journal of Magnetic Resonance Imaging. in press.
  2. Bouilleret V, Hogan RE, Velakoulis D, Salzberg M, Wang L, Egan G, O’Brien TJ, Jones NC. Morphometric abnormalities and hyperanxiety in genetically epileptic rats: a model of psychiatric comorbidity? Neuroimage. 2009; 45:267-274.

Holtzman

  1. Tarawneh R, Holtzman DM. (2009) Critical issues for successful immunotherapy in Alzheimer’s disease: development of biomarkers and methods for early detection and intervention. CNS Neurol Disord Drug Targets. Apr;8(2):144-59. PMID: 19355934
  2. Kim J, Basak JM, Holtzman DM. (2009) The role of apolipoprotein E in Alzheimer’s disease. Neuron. Aug 13;63(3):287-303. PMID: 19679070
  3. Perrin RJ, Fagan AM, Holtzman DM. (2009) Multimodal techniques for diagnosis and prognosis of Alzheimer’s disease. Nature. 461:916-22.
  4. Holtzman DM. A surrogate marker for Abeta42 production in the CNS.. EMBO Mol Med. 2009 Jul;1(4):195-7.
  5. Holtzman DM. Cerebrospinal fluid beta-amyloid 42, Tau, and P-tau: confirmation now realization. Arch Neurol. 2009 Dec;66(12):1552-3.
  6. 1Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC, Yarasheski KE, Friedrich SW, Demattos RB, May PC, Paul SM, Holtzman DM. (2009)
    A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system.
    Ann Neurol. 66(1):48-54. PMID: 19360898
  7. Mandrekar S, Jiang Q, Lee CY, Koenigsknecht-Talboo J, Holtzman DM, Landreth GE. 2009 Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis.
    J Neurosci. Apr 1;29(13):4252-62. PMID: 19339619
  8. Fagan AM, Head D, Shah AR, Marcus D, Mintun M, Morris JC, Holtzman DM. (2009) Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol. Feb;65(2):176-83.
  9. West T, Stump S, Lodygensky G, Neil JJ, Deshmukh M Holtzman DM. (2009) Lack of X-linked inhibitor of apoptosis protein leads to increased apoptosis and tissue loss following neonatal hypoxic-ischemic brain injury. ASN Neuro. Apr 14;1(1). pii: e00004. doi: 10.1042/AN20090005. PMID: 19570023
  10. Snider BJ, Fagan AM, Roe C, Shah AR, Grant EA, Xiong C, Morris JC, Holtzman DM. (2009) Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol. 66(5):638-45.
  11. Aslund A, Sigurdson CJ, Klingstedt T, Grathwohl S, Bolmont T, Dickstein DL, Glimsdal E, Prokop S, Lindgren M, Konradsson P, Holtzman DM, Hof PR, Heppner FL, Gandy S, Jucker M, Aguzzi A, HammarstroÌ√m P, Nilsson KP. (2009) Novel Pentameric Thiophene Derivatives for in Vitro and in Vivo Optical Imaging of a Plethora of Protein Aggregates in Cerebral Amyloidoses. ACS Chem Biol. Jul 30. [Epub ahead of print] PMID: 19624097
  12. Cao C, Cirrito JR, Lin X, Wang L, Verges DK, Dickson A, Mamcarz M, Zhang C, Mori T, Arendash GW, Holtzman DM, Potter H. (2009) Caffeine Suppresses Amyloid-beta Levels in Plasma and Brain of Alzheimer’s Disease Transgenic Mice. J Alzheimers Dis. Jul;17(3):681-97. PMID: 19581723
  13. Yuede CM, Zimmerman SD, Dong H, Kling MJ, Bero AW, Holtzman DM, Timson BF, Csernansky JG. (2009) Effects of voluntary and forced exercise on plaque deposition, hippocampal volume, and behavior in the Tg2576 mouse model of Alzheimer’s disease. Neurobiol Dis. 35(3):426-32. Epub 2009 Jun 12.
  14. Britschgi M, Olin CE, Johns HT, Takeda-Uchimura Y, LeMieux MC, Rufibach K, Rajadas J, Zhang H, Tomooka B, Robinson WH, Clark CM, Fagan AM, Galasko DR, Holtzman DM, Jutel M, Kaye JA, Lemere CA, Leszek J, Li G, Peskind ER, Quinn JF, Yesavage JA, Ghiso JA, Wyss-Coray T. (2009) Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer’s disease. Proc Natl Acad Sci USA Jul 21;106(29):12145-50. Epub 2009 Jul 6. PMID: 19581601
  15. Yan P, Bero AW, Cirrito JR, Xiao Q, Hu X, Wang Y, Gonzales E, Holtzman DM, Lee JM. (2009) Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. J Neurosci. 29(34):10706-14.
  16. Kang J, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, Fujiki N, Nishino S, Holtzman DM. (2009) Amyloid- Dynamics are Regulated by Orexin and the Sleep-Wake Cycle. Science 326:1005-7.
  17. Hinrichs AL, Mintun MA, Head D, Fagan AM, Holtzman DM, Morris JC, Goate AM.
    Cortical Binding of Pittsburgh Compound B, an Endophenotype for Genetic Studies of Alzheimer’s Disease. Biol Psychiatry. 2009 Nov 4. [Epub ahead of print]
  18. Duchek JM, Balota DA, Tse CS, Holtzman DM, Fagan AM, Goate AM. The utility of intraindividual variability in selective attention tasks as an early marker for Alzheimer’s disease.
    Neuropsychology. 2009 Nov;23(6):746-58.
  19. Clifford DB, Fagan AM, Holtzman DM, Morris JC, Teshome M, Shah AR, Kauwe JS.
    CSF biomarkers of Alzheimer disease in HIV-associated neurologic disease.
    Neurology. 2009 Dec 8;73(23):1982-7. Epub 2009 Nov 11.
  20. Lodygensky G, West T, Stump M, Holtzman DM, Inder T, Neil J. In vivo MRI analysis of an inflammatory injury in the developing brain. Brain Behav Immun. 2009 Nov 26. [Epub ahead of print]
  21. Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, Mach RH, Marcus D, Morris JC, Holtzman DM. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer’s disease.
    EMBO Mol Med. 2009 Nov;1(8-9):371-80.
  22. Zeng LH, Bero AW, Zhang B, Holtzman DM, Wong M. Modulation of Astrocyte Glutamate Transporters Decreases Seizures in a Mouse Model of Tuberous Sclerosis Complex.
    Neurobiol Dis. 2009 Dec 29. [Epub ahead of print]
  23. Cairns NJ, Ikonomovic MD, Benzinger T, Storandt M, Fagan AM, Shah A, Schmidt RE, Perry A, Reinwald LT, Carter D, Felton A, Holtzman DM, Mintun MA, Klunk WE, Morris JC.
    Absence of Pittsburgh Compound B Detection of CerebralAmyloid Beta in a Patient With Clinical, Cognitive, and Cerebrospinal FluidMarkers of Alzheimer Disease. Arch Neurol. 2009 Dec;66(12):1557-1562.
  24. Steele JW, Kim SH, Cirrito JR, Verges DK, Restivo JL, Westaway D, Fraser P, St George Hyslop P, Sano M, Bezprozvanny I, Ehrlich ME, Holtzman DM, Gandy S. Acute dosing of latrepirdine (DimebonTM), a possible Alzheimer therapeutic, elevates extracellular amyloid-beta levels in vitro and in vivo. Mol Neurodegener. 2009 Dec 17;4(1):51. [Epub ahead of print]
  25. Cairns NJ, Ikonomovic MD, Benzinger T, Storandt M, Fagan AM, Shah AR, Reinwald LT, Carter D, Felton A, Holtzman DM, Mintun MA, Klunk WE, Morris JC. Absence of Pittsburgh Compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol. 2009 Dec;66(12):1557-62.
  26. Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, Fagan AM, Holtzman DM, Mintun MA. Pittsburgh Compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol. 2009 Dec;66(12):1469-75.
  27. Kim J, Castellano JM, Jiang H, Basak JM, Parsadanian M, Pham V, Mason SM, Paul SM, Holtzman DM. Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance.
    Neuron. 2009 Dec 10;64(5):632-44.

Hyrc

  1. Wu S., Hyrc KL., Moulder KL., Lin Y., Warmke T. and Snider BJ., Cellular calcium deficiency plays a role in neuronal death caused by proteasome inhibitors. J. Neurochem. – 2009;109;125-136.
  2. Zhang HX., Hyrc KL,, Thio LL., The Glycine Transport Inhibitor Sarcosine Is an NMDA Receptor Co-agonist that Differs from Glycine – J. Physiology – in print

Kotzbauer

  1. Mancuso D.J., Kotzbauer P.T., Wozniak D.F., Sims H.F., Jenkins C.M., Guan S., Han X., Yang K., Sun G., Malik I., Conyers S., Green K.G., Schmidt R.E., Gross R.W., Genetic ablation of calcium-independent phospholipase A2 gamma leads to alterations in hippocampal cardiolipin content and molecular species distribution, mitochondrial degeneration, autophagy and cognitive dysfunction. Journal of Biological Chemistry 284(51):35632-44, 2009

Larsen

  1. Larsen DP, Butler AC, Roediger HL. “Repeated testing improves long-term retention over repeated study: a randomized, controlled trial.” In submission.

Lee

  1. Ford A.L., Connor L.T., Tan D.K., Williams J.A., Lee J.-M., Nassief A.M., Resident-based acute stroke protocol is expeditious and safe, Stroke, 40(40):1512-4, 2009.
  2. Zhang R., Hu X., Khant H., Ludtke S.J., Chiu W., Schmid M.F., Frieden C., Lee J.-M., Inter-protofilament interactions between Alzheimer’s Aβ1-42 peptides in amyloid fibrils revealed by cryo-EM, Proc Natl Acad Sci, 24:106(12):4653-8, 2009.

Lopate

  1. Lopate G, Baloh RH, Al-Lozi MT, Miller TM, Filho JAF, Ni O, Leston A, Florence J, Schierbecker J, Allred P. Familial ALS with extreme phenotypic variability due to the I113T SOD1 mutation. Amyotroph Lateral Scler (in press).

Morris

  1. Galvin JE, Meuser TM, Coats MA, Bakal DA, Morris JC. The “Portable” CDR: Translating the clinical dementia rating interview into a PDA format. Alzheimer Dis Assoc Disord 2009; 23:44-49.
  2. Rapoport MJ, Herrmann N, Molnar F, Rochon PA, Juurlink DN, Zagorski B, Seitz D, Morris JC, Redelmeier DA. Psychotropic medications and motor vehicle collisions in patients with dementia. JAGS 2008; 56:1968-1970.
  3. Dickerson BC, Bakkour A, Salat D, Feczko E, Pacheco J, Greve DN, Grodstein F, Wright CI, Blacker D, Rosas HD, Sperling RA, Atri A, Growdon JH, Hyman BT, Morris JC, Fischl B, Buckner RL. The cortical signature of Alzheimer’s disease: Regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cerebral Cortex 2009; 19:497.510.
  4. Dickerson BC, Feczko E, Augusinack JC, Pacheco J, Morris JC, Fischl B, Buckner RL. Differential effects of aging and Alzheimer’s disease on medial temporal lobe neocortical thickness and surface area. Neurobiol. Aging 2009; 30:432-440.
  5. Kauwe JSK, Wang J, Mayo K, Morris JC, Fagan AM, Holtzman DM, Goate AM. Alzheimer’s disease risk variants show association with cerebrospinal fluid amyloid beta. Neurogenetics 2009; 10:13-17.
  6. Fagan AM, Head, D, Shah AR, Marcus D, Mintun M, Morris JC, Holtzman DM. Decreased cerebrospinal fluid Aβ42 correlates with brain atrophy in cognitively normal elderly. Ann Neurol 2009; 65:176-183.
  7. Bakkour A, Morris JC, Dickerson BC. The cortical signature of prodromal AD: Regional thinning predicts mild AD dementia. Neurology 2009; 72:1048-1055.
  8. Wilkins CH, Birge SJ, Sheline YI, Morris JC. Vitamin D deficiency is associated with worse cognitive performance and lower bone density in older African Americans. J. Natl Med Assoc 2009;101:349-354.
  9. Andrieu S, Coley N, Aisen P, Carrillo M, DeKosky S, Durga J, Fillit H, Frisoni G, Froelich L, Gauthier S, Jones R, Jonsson L, Khachaturian Z, Morris JC, Orgogozo J-M, Ousset P-J, Robert P, Salmon E, Sampaio C, Verhey F, Wilcock G, Vellas B. Methodological issues in primary prevention trials for neurodegenerative dementia. J. Alz Dis 2009; 16:235-270.
  10. Price JL, McKeel DW, Buckles VD, Roe CM, Xiong C, Grundman M, Hansen LA, Petersen RC, Parisi JE, Dickson DW, Smith CD, Davis DG, Schmitt FA, Markesbery WR, Kaye J, Kurlan R, Hulette C, Kurland BF, Higdon R, Kukull W, Morris JC. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging 2009;30:1026-1036.
    Wilkins CH, Roe CM, Morris JC. A brief clinical tool to assess physical function: The mini-physical performance test. Arch.Gerontol.Geriatr. 2009;(doi:10.1016/j.archger.2009.02.2006)
  11. Schneider L, Raman R, Schmitt FA, Doody R, Insel P, Clark CM, Morris JC, Reisberg B, Petersen RC, Ferris SH. Characteristics and performance of a modified version of the ADCS-CGIC CIBIC + for Mild Cognitive Impairment clinical Trials. Alz Dis Assoc Disorders 2009; 23:260-267.
  12. Malmstrom TK, Miller DK, Coats MA, Jackson, Miller JP, Morris JC. Informant based dementia screening in a population-based sample of African Americans. Alzheimer Dis Assoc Dis 2009; 23:117-123.
  13. Wang L, Khan A, Csernansky JG, Fischl B, Miller MI, Morris JC, Beg MF. Fully-automated, multi-stage hippocampus mapping in very mild Alzheimer Disease. Hippocampus, June 2009;19:541-548.
  14. Weintraub S, Salmon D, Mercaldo N, Ferris S, Graff-Radford N, Chui H, Cummings J, DeCarli C, Foster NL, Galasko D, Peskind E, Dietrich W, Beekly DL, Kukull B, Morris JC. The Alzheimer’s Disease Centers’ Uniform Data Set (UDS): The Neuropsychological Test Battery. Alzheimer Dis Assoc Dis 2009; 23:91-101.
  15. Williams MM, Roe CM, Morris JC. Stability of the Clinical Dementia Rating: 1979-2007. Archives of Neurology 2009; 66:773-777.
  16. Snider BJ, Fagan AM, Roe CM, Shah AR, Grant EA, Xiong C, Morris JC, Holtzman DM. CSF biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Archives of Neurology 2009; 66:638-645.
  17. Stark S, Landsbaum A, Palmer JL, Somerville EK, Morris JC. Client-centred home modifications improve daily activity performance of older adults. Can J of Occup Ther 2009;76:235-245.
  18. Sheline YI, Raichle ME, Snyder AZ, Morris JC, Head D, Wang S, Mintun MA. Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol Psychiatry 2009. doi:10.1016/j.biopsych.2009.08.024.
  19. Johnson DK, Storandt M, Morris JC, Galvin JE. Longitudinal study of the transition from healthy aging to AD. Arch Neurology 2009; 66:1254-1259.
  20. Ghoshal N, Cali I, Perrin RJ, Josephson SA, Sun N, Gambetti P, Morris JC. Co-distribution of Amyloid plaques and spongiform degeneration in familial Creutzfeldt-Jakob disease with the E200K-129M Haplotype. Archives of Neurology 2009; 66:1240-1246.
  21. Avidan MS, Searleman AC, Storandt M, Barnett K, Vannucci A, Saager L, Xiong C, Grant EA, Kaiser D, Morris JC, Evers AS. Long-term cognitive decline in older subjects was not attributable to noncardiac surgery or major illness. Anesthesiology 2009; 111:963-9.
  22. Cairns NJ, Ikonomovic, MD, Benzinger T, Storandt M, Fagan AM, Shah AR, Taylor-Reinwald L, Carter D, Felton A, Holtzman DM, Mintun MA, Klunk WE, Morris JC. Absence of Pittsburgh Compound B detection of cerebral amyloid β in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer’s Disease. Archives of Neurology 2009; 66:1557-1562.
  23. Morris JC; Roe CM; Grant EA; Head D; Storandt M; Goate AM; Fagan AM; Holtzman DM;Mintun MA. Pittsburgh Compound B Imaging and Prediction of Progression from Cognitive Normality to Symptomatic Alzheimer’s Disease. Archives Neurology 2009; 66:1469-1475.
  24. Storandt M, Mintun M, Head D, Morris JC. Cognitive decline and brain volume loss as signatures of cerebral Amyloid-β peptide deposition identified with Pittsburgh Compound B. Archives of Neurology 2009; 66:1476-1481.
  25. Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, Mach RH, Marcus D, Morris JC, Holtzman DM. Cerebrospinal fluid tau and ptau181 increase with coritical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer’s disease. EMBO Mol Med 2009,1:371-380.
  26. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere M, Pahwa JS, Moskvina V, DowzellK, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Ribinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schurmann B, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frolich L, Hampel H, Hull M, Rujescu D, Goate AM, Kauwe JSK, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, DeDeyn P, van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Muhleisen TW, Nothen MM, Moebus S, Jockel K-H, Klopp N, Wichmann H-E, Carrasquillo MM, Pankratz VS, Younkin SG, Holmans PA, O’Donovan M, Owen MJ, Williams J. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nature Genetics 2009; doi:10.1038/ngXXXX.
  27. Gitcho MA, Bigio EH, Mishra M, Johnson N, Weintraub S, Mesulam M, Rademakers R, Chakraverty S, Cruchaga C, Morris JC, Goate AM, Cairns NJ. TARDB 3’UTR mutation in autopsy-confirmed frontotemporallobar degenerationwithTDP-43 proteinopathy. Acta Neuropathologica 2009; 118:633-645.

Naismith

Peer Reviewed Manuscripts

  1. Klawiter E, Cross AH, Naismith RT. MS medication efficacy in the modern era: is the new 66% just the old 33%? Neurology 2009;73:984-990..
  2. Naismith RT, Tutlam NT, Xu J, Shepherd JB, Klawiter EC, Song SK, Cross AH. Optical coherence tomography is less sensitive than visual evoked potentials in optic neuritis. Neurology 2009;73:53-58.
  3. Klawiter EC, Alvarez E, Xu J, Paciorkowski A, Zhu L, Cross AH, Naismith RT. NMO IgG detected in CSF in seronegative neuromyelitis optica. Neurology 2009;72:1101-1102.
  4. Naismith RT, Tutlam NT, Xu J, Klawiter EC, Shepherd J, Trinkaus K, Song SK, Cross AH. Optical coherence tomography differentiates neuromyelitis optica from multiple sclerosis. Neurology 2009;72:1077-1082.
  5. Naismith RT, Tutlam NT, Weihl CC, Shepherd J, Cross AH. Acute and bilateral blindness due to optic neuropathy associated with copper deficiency. Arch Neurol 2009;66(8):1025-1027.
  6. Naismith RT, Xu J, Benzinger T, Shimony J, Shpherd J, Trinkaus K, Cross AH, Song SK. Disability in optic neuritis correlates with diffusion tensor derived directional diffusivities. Neurology 2009;72:589-594.

Abstracts

  1. Naismith RT, Xu J, Tutlam NT, Cross AH, Song SK.. Increased radial diffusivity in remote optic neuritis discriminates clinical visual outcomes. ECTRIMS Dusseldorf 2009.
  2. Naismith RT, Xu J, Tutlam NT, Trinkaus K, Song SK, Cross AH. Increased Diffusivity in Acute MS Lesions Predicts Risk for Black Hole Progression. ECTRIMS Dusseldort 2009.
  3. Qian Peiqing, Cross AH, Naismith RT. Assessment of Pain in Neuromyelitis Optica. ACTRIMS Atlanta 2009.
  4. Naismith RT, Xu J, Tutlam NT, Trinkaus K, Song SK, Cross AH. Diffusion Tensor imaging predicts severe tissue injury in acute MS lesions. Platform Presentation. ACTRIMS Atlanta 2009.
  5. Klawiter E, Trinkaus K, Liang HF, Shu-Wei S, Budde M, Naismith RT, Schmidt R, Song SK, Cross AH, Benzinger T. Axial and radial diffusivity as MR biomarkers of axonal and myelin injury in ex-vivo multiple scleorsis cervical spinal cords. AAN Seattle 2009.
  6. Xu J, Klawiter EC, Benzinger TLS, Naismith RT, Song SK, Cross AH. Directional diffusivities in human spinal cord correlate with functional outcome. ISMRM 2009. Honolulu.
  7. Xu J, Klawiter EC, Naismith RT, Benzinger TLS, Cross AH, Song SK. Assessment of spinal cord injury via diffusion MRI. Keystone Symposia on MS, Sante Fe, AZ, 2009.
  8. Klawiter E, Trinkaus K, Hsiao-Fang L, Shu-Wei S, Budde M, Naismith R, Schmidt R, Cross A, Song SK, Benzinger T. Axial and radial diffusivity as MR biomarkers of axonal and myelin injury in ex-vivo multiple sclerosis cervical spinal cords. AAN 2009. Seattle.
  9. Cross AH, Piccio L, Klein RS, Parks BJ, Lyons JA, Trinkaus KT, Naismith RT. B cell depletion in MS patients using Rituximab (antiCD20) Keystone 2009, Santa Fe.

Neil

  1. Neil JJ and Inder TE, “Novel imaging techniques,” Clinical and Scientific Aspects of Neurodevelopmental Disabilities (International Review of Child Neurology) (M Shevell, ed.) Mac Keith Press, London, in press.
  2. Neil JJ and Ackerman JJH, “Diffusion Sensitive Magnetic Resonance Imaging of the Central Nervous System” Handbook of Neurochemistry and Molecular Neurobiology, Springer, New York, in press.
  3. Ackerman JJH and Neil JJ, “Biophysics of Diffusion in Cells,” Diffusion MRI (D Jones, ed.) Oxford University Press, Oxford, in press
  4. West T, Stump M, Lodygensky G, Neil J, Deshmukh M, Holtzman DM, “Lack of X-linked Apoptosis Inhibitor Protein Leads to Increased Apoptosis and Tissue Loss Following Neonatal Hypoxic-Ischemic Brain Injury,” ASN Neuro, in press.

Parks

  1. Klawiter MD, Eric C; Alvarez, III MD PhD, Enrique; Xu PhD, Junqian; Paciorkowski MD, Alex R; Zhu MD PhD, Lirong; Parks MD, Becky J; Cross MD, Anne H; Naismith MD, Robert T. NMO-IgG Detected in CSF in Seronegative Neuromyelitis Optica. Neurology,2009 Mar 24;72 (12):1101-3.
  2. Fenoglio C, Scalabrini D, Piccio L, De Riz M, Venturelli E, Cortini F, Villa C, Serpente M, Parks B, Rinker J, Cross AH, Bresolin N, Scarpini E, Galimberti D. Candidate gene analysis of selectin cluster in patients with multiple sclerosis. J. Neurol. 2009 Feb 25.

Perlmutter

  1. Kumar N, Lee JJ, Perlmutter JS, Derdeyn CP. Cervical carotid and Circle of Willis arterial anatomy of Macaque monkeys: A comparative anatomy study. Anatomic Record. 292:976-84,2009.
  2. Xiao J, Bastian RW, Perlmutter JS, Racette BA, Tabbal SD, Karimi M, Paniello RC, Blitzer A, Batish SD, Wszolek ZK, Uitti RJ, Hedera P, Simon DK, Tarsy D, Truong DD, Frei KP, Pfeiffer RF, Gong S, Zhao Y, LeDoux MS. High-Throughput Mutational Analysis of TOR1A in Primary Dystonia. BMC Med Gen, 10:24 2009. PMC2661056
  3. Racette BA, Good LM, Kissel AM, Criswell SR, Perlmutter JS. A population based study of parkinsonism in an Amish community. Neuroepidemiology 33:225-230,2009.
  4. Xu J, Chu W, Tu Z, Jones LA, Luedtke RR, Perlmutter JS, Mintun MA, Mach RH. [(3)H]4-(Dimethylamino)-N-[4-(4-(2-methoxyphenyl)piperazin- 1-yl)butyl]benzamide, a selective radioligand for dopamine D(3) receptors. I. In vitro characterization. Synapse 63:717-728, 2009.
  5. Paniello RC, Edgar JD, Perlmutter JS: Vocal exercise vs voice rest following botulinum toxin injections: a randomized crossover trial. Ann Otol Rhino Laryngo. 18:759-783., 2009.
  6. Xiao J, Bastian RW, Perlmutter JS, Racette BA, Tabbal SD, Karimi M, Paniello RC, Wszolek ZK, Uitti RJ, Van Gerpen JA, Simon DK, Tarsy D, Hedra P, Truong DD, Frei KP, Batish SD, Blitzer A, Pfeiffer RF, Gong S, LeDoux MS: Novel THAP1 sequence variants in primary dystonia. Neurology, in press, 2009.

Pestronk

  1. Temiz P, Weihl CC, Pestronk A. Inflammatory myopathies with mitochondrial pathology and protein aggregates. J Neurol Sci 2009;278:25-29.
  2. Nozaki K, Pestronk A. High Aldolase with Normal Creatine Kinase in serum predicts a Myopathy with Perimysial Pathology. J Neurol Neurosurg Psychiatry 2009;80:904-908.
  3. Weihl CC, Pestronk A, Kimonis VE. Valosin-containing protein disease: inclusion body myopathy with Paget’s disease of the bone and fronto-temporal dementia. Neuromuscul Disord 2009;19:308-315.
  4. Kaufmann P, Thompson JL, Levy G, Buchsbaum R, Shefner J, Krivickas LS, Katz J, Rollins Y, Barohn RJ, Jackson CE, Tiryaki E, Lomen-Hoerth C, Armon C, Tandan R, Rudnicki SA, Rezania K, Sufit R, Pestronk A, Novella SP, Heiman-Patterson T, Kasarskis EJ, Pioro EP, Montes J, Arbing R, Vecchio D, Barsdorf A, Mitsumoto H, Levin B; QALS Study Group. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol 2009;66:235-244.
  5. Zaidman CM, Al-Lozi M, Pestronk A. Peripheral nerve size in normals and patients with polyneuropathy: An ultrasound study. Muscle Nerve 2009 Aug 20.
  6. Margeta M, Connolly AM, Winder TL, Pestronk A, Moore SA. Cardiac pathology exceeds skeletal muscle pathology in two cases of limb-girdle muscular dystrophy type 2I. Muscle Nerve 2009;40:883-889.
  7. WenKaspar R, Allen HD, Ray WC, Alvarez CE, Kissel JT, Pestronk A, Weiss RB, Flanigan KM, Mendell JR, Montanaro F. Analysis of Dystrophin Deletion Mutations Predicts Age of Cardiomyopathy Onset in Becker Muscular Dystrophy. Circ Cardiovasc Genet 2009 Sep 30.
  8. Flanigan KM, Dunn DM, von Niederhausern A, Soltanzadeh P, Gappmaier E, Howard MT, Sampson JB, Mendell JR, Wall C, King WM, Pestronk A, Florence JM, Connolly AM, Mathews KD, Stephan CM, Laubenthal KS, Wong BL, Morehart PJ, Meyer A, Finkel RS, Bonnemann CG, Medne L, Day JW, Dalton JC, Margolis MK, Hinton VJ, Weiss RB; the United Dystrophinopathy Project Consortium. Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort. Hum Mutat 2009;30:1657-1666.
  9. Buchsbaum R, Kaufmann P, Barsdorf AI, Arbing R, Montes J, Thompson JL; QALS Study Group. Web-based data management for a phase II clinical trial in ALS. Amyotroph Lateral Scler. 2009;10:374-377.

Petersen

  1. Church, J.A., Fair, D.A., Dosenbach. N.U.F., Cohen, A.L., Miezin, F.M., Petersen, S.E., Schlaggar, B.L. (2009) Control networks in pediatric tourette syndrome show immature and anomalous patterns of functional connectivity. Brain, 132:225-238.
  2. Dosenbach, N.U.F., Petersen, S.E. (2009) “Attentional Networks”. In Squire, L.R. (ed.) Encyclopedia of Neuroscience Vol. 1, pp. 655-660.
  3. Ihnen, S.K.Z., Church, J.A., Petersen, S.E., Schlaggar, B.L. (2009) Lack of generalizability of sex differences in the fMRI BOLD activity associated with language processing in adults. NeuroImage, 45(3):1020-1032.
    Donaldson, D., Petersen S. Remember the source: dissociating frontal and parietal contributions to episodic memory. Epub, J of Cognitive Neuroscience.
  4. White, B.R., Snyder, A.Z., Cohen, A.L., Petersen, S.E., Raichle, M.E., Schlaggar, B.L., Culver, J.P. (2009) Resting-state functional connectivity in the human brain revealed with diffuse optical tomography. NeuroImage, 47:148-56.
  5. Fair, D.A., Cohen, A.L., Power, J.D., Dosenbach, N.U.F., Church, J.A., Miezin, F.M., Schlaggar, B.L., Petersen, S.E. (2009) Functional Brain Networks Develop from a “Local to Distributed” Organization. Epub, PLOS Computational Biology.
  6. Fair, D.A., Choi, A.H., Dosenbach, Y.B., Coalson, R.S, Miezin, F.M., Petersen, S.E., Schlaggar, B.L. (2009) The functional organization of trial-related activity in lexical processing after early left hemispheric brain lesions: An event-related fMRI study. Accepted, Brain and Language.
  7. Church, J.A., Wenger, K.K., Dosenbach, N.U.F., Miezin, F.M., Petersen, S.E., Schlaggar, B.L. (2009) Task control signals in pediatric Tourette syndrome show evidence of immature and anomalous functional activity. Accepted, Frontiers in Human Neuroscience.

Piccio

  1. Fenoglio C, Scalabrini D, Piccio L, De Riz M, Venturelli E, Cortini F, Villa C, Serpente M, Parks B, Rinker J, Cross AH, Bresolin N, Scarpini E, Galimberti D. Candidate gene analysis of selectin cluster in patients with multiple sclerosis. J Neurol 2009;256 (5):832-3.
  2. De Jager PL, Jia X, Wang J, de Bakker PI, Ottoboni L, Aggarwal NT, Piccio L, Raychaudhuri S, Tran D, Aubin C, Briskin R, Romano S; International MS Genetics Consortium, Baranzini SE, McCauley JL, Pericak-Vance MA, Haines JL, Gibson RA, Naeglin Y, Uitdehaag B, Matthews PM, Kappos L, Polman C, McArdle WL, Strachan DP, Evans D, Cross AH, Daly MJ, Compston A, Sawcer SJ, Weiner HL, Hauser SL, Hafler DA, Oksenberg JR. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet. 2009;41(7):776-82.
  3. Fenoglio C, Galimberti D, Cortini F, Kauwe JS, Cruchaga C, Venturelli E, Villa C,
    Serpente M, Scalabrini D, Mayo K, Piccio LM, Clerici F, Albani D, Mariani C, Forloni G, Bresolin N, Goate AM, Scarpini E. Rs5848 Variant Influences GRN mRNA Levels in Brain and Peripheral Mononuclear Cells in Patients with Alzheimer’s Disease. J Alzheimers Dis. 2009; Epub ahead of print.
  4. De Riz M, Galimberti D, Fenoglio C, Piccio LM, Scalabrini D, Venturelli E, Pietroboni A, Piola M, Naismith RT, Parks BJ, Fumagalli G, Bresolin N, Cross AH, Scarpini E. Cerebrospinal fluid progranulin levels in patients with different multiple sclerosis subtypes. Neurosci Lett. 2009; Epub ahead of print.

Racette

  1. Hobsen AJ, Sterling DA, Emo B, Evanoff BA, Sterling CS, Good L, Seixas N, Checkoway H, Racette BA. Validity and Reliability of an Occupational Exposure Questionnaire for Parkinsonism in Welders. J Occup Environ Hyg 2009;6(6):324-331.
  2. Xiao J, Bastian RW, Perlmutter JS, Racette BA, Tabbal SD, Karimi M, Paniello RC, Blitzer A, Batish SD, Wszolek ZJ, Uitti RJ, Hedera P, Simon DK, Tarsy D, Truong DD, Frei KP, Pfeiffer RF, Gong S, ZhaoY LeDoux MS. High-Throughput Mutational Analysis of TOR1A in Primary Dystonia. BMC Medical Genetics 2009;10:24.
  3. Racette BA, Good LM, Kissel AM, Criswell SR, Perlmutter JS. A Population Based Study of Parkinsonism in an Amish Community. Neuroepidemiology 2009; 33(3):225-230.
  4. Willis AW, Sterling C, Racette BA. Conjugal Parkinson Disease: A Case Series with Environmental Risk Factor Analysis. Parkinsonism Relat Disord 2009; in press.
  5. Xiao J, Zhao Y, Bastian RW, Perlmutter JS, Racette BA, Tabbal SD, Karimi M, Paniello RC, Wszolek K, Uitti RJ, Van Gerpen JA, Simon DK, Tarsy D, Hedera P, Truong DD, Frei KP, Batish SD, Blitzer A, Pfeiffer RF, Gong S, LeDoux MS. Sequence Variants in Primary Dystonia. Neurology 2009;in press.
  6. Simón-Sánchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, Paisan-Ruiz C, Lichtner P, Scholz SW, Hernandez DG, Krüger R, Federoff M, Klein C, Goate A, Perlmutter J, Bonin M, Nalls MA, Illig T, Gieger C, Houlden H, Steffens M, Okun MS, Racette BA, Cookson MR, Foote KD, Fernandez HH, Traynor BJ, Schreiber S, Arepalli S, Zonozi R, Gwinn K, van der Brug M, Lopez G, Chanock SJ, Schatzkin A, Park Y, Hollenbeck A, Gao J, Huang X, Wood NW, Lorenz D, Deuschl G, Chen H, Riess O, Hardy JA, Singleton AB, Gasser T. Genome-wide association study reveals genetic risk underlying Parkinson’s disease. Nat Genet. 2009; 41(12):1308-12.
  7. Willis AW, Evanoff BA, Lian M, Criswell SR, Racette BA. Geographical and Ethnic Variation in PD: A Population-Based Study of U.S. Medicare Beneficiaries. Neuroepidemiology 2010; in press.

Schlaggar

  1. Schlaggar, B.L., Church J.A. (2009) Functional Neuroimaging Insights into the Development of Skilled Reading. Current Directions in Psychological Sciences. 18: 21-26.
  2. Church, J.A., Fair, D.A., Dosenbach. N.U.F., Cohen, A.L., Miezin, F.M., Petersen, S.E., Schlaggar, B.L. (2009) Control networks in pediatric Tourette syndrome show immature and anomalous patterns of functional connectivity. Brain, 132:225-238.
  3. Ihnen, S.K.Z., Church, J.A., Petersen, S.E., Schlaggar, B.L. (2009) Lack of generalizability of sex differences in the fMRI BOLD activity associated with language processing in adults. NeuroImage, 45(3):1020-1032.
  4. White, B.R., Snyder, A.Z., Cohen, A.L., Petersen, S.E., Raichle, M.E., Schlaggar, B.L., Culver, J.P. (2009) Resting-state functional connectivity in the human brain revealed with diffuse optical tomography. In Press, NeuroImage.
  5. Fair, D.A., Cohen, A.L., Power, J.D., Dosenbach, N.U.F., Church, J.A., Miezin, F.M., Schlaggar, B.L., Petersen, S.E. (2009) Functional Brain Networks Develop from a “Local to Distributed” Organization. PLoS Comput Biol 5(5): e1000381. doi:10.1371/journal.pcbi.1000381

Schwedt

  1. Schwedt TJ. Endothelial dysfunction and migraine. Cephalalgia 2009;29:997-1002.
  2. Trentman TL, Rosenfeld DM, Vargas BB, Schwedt TJ, Zimmerman RS, Dodick DW. Greater occipital nerve stimulation via the Bion® Microstimulator: implantation technique and stimulation parameters. Clinical trial: NCT00205894. Pain Physician 2009;12:621-628.
  3. Schwedt TJ, Dodick DW. Advanced neuroimaging of migraine. Lancet Neurology 2009;8:560-568.
  4. Schwedt TJ. The migraine association with cardiac anomalies, cardiovascular disease, and stroke. Neurologic Clinics 2009;27:513-523.
  5. Schwedt TJ. Neurostimulation for primary headache disorders. Current Neurology and Neuroscience Reports 2009;9:101-107.
  6. Schwedt TJ, Shapiro RE. Funding of research on headache disorders by the National Institutes of Health. Headache 2009;49:162-169.
  7. Dodick DW, Schwedt T. Headache: challenging conventional wisdom. Lancet Neurology 2009;8: 12-14.

Shulman

  1. Rengachary, J., d`Avossa G., Sapir, A., Shulman, G. L., and Corbetta, M. (2009) Is the Posner reaction time test more accurate than clinical tests in detecting left neglect in acute and chronic stroke? Archives of Physical Medicine and Rehabilitation, 90:2081-2088.
  2. Sylvester, C. M, Shulman, G. L., Jack, A. I., and Corbetta, M. (2009) Anticipatory and stimulus-evoked BOLD modulations related to spatial attention reflect a common additive signal. Journal of Neuroscience, 29:10671-10682.
  3. Shulman, G.L., Astafiev, S. V., Franke, D., Pope, D. L. W., Snyder, A. Z., McAvoy, M. P., and Corbetta, M. (2009) Interaction of stimulus-driven reorienting and expectation in ventral and dorsal frontoparietal and basal ganglia-cortical networks. Journal of Neuroscience, 29:4392-4407.

Tabbal

  1. Earhart GM, Clark BR, Tabbal SD, Perlmutter JS. Gait and balance in essential tremor: variable effects of bilateral thalamic stimulation. Movement Disorders. 24(3): 386-91, February 2009.
  2. Xiao J, Bastian RW, Perlmutter JS, Racette BA, Tabbal SD. Karimi M, Paniello RC, Blitzer A, Batish SD, Wszolek ZK, Uitti RJ, Hedera P, Simon DK, Tarsy D, Truong DD, Frei KP, Pfeiffer RF, Gong S, Zhao Y, LeDoux MS. High-throughput mutational analysis of TOR1A in primary dystonia. BMC Medical Genetics, 10:24, March 2009.

Thio

  1. Thio LL, Rho JM, Stafstrom CE. The ketogenic diet. Pediatric Update 2009; 29.

Videen

  1. Zazulia AR, Videen TO, Powers WJ. Transient focal increase in perihematomal glucose metabolism after acute human intracerebral hemorrhage. Stroke 2009; 40:1638-43.
  2. Zipfel GJ, Sagar J, Miller JP, Videen TO, Grubb RL Jr, Dacey RG Jr, Derdeyn CP. Cerebral hemodynamics as a predictor of stroke in adult patients with moyamoya disease: a prospective observational study. Neurosurg Focus 2009; 26(4):1-5.
  3. Dromerick AW, Lang CE, Birkenmeier RL, Wagner JM, Miller JP, Videen TO, Powers WJ, Wolf SL, Edwards DF. Very early constraint induced movement during stroke rehabilitation (VECTORS): A single center RCT. Neurology 2009 (in press).
  4. Dhar R, Zazulia AR, Videen TO, Zipfel GJ, Derdeyn CP, Diringer M. Red blood cell transfusion increases cerebral oxygen delivery in anemic patients with subarachnoid hemorrhage. Stroke 2009 (in press).

Wong

  1. Shakkottai VG, Xiao M, Xu L, Wong M, Nerbonne JM, Ornitz DM, Yamada KA. FGF14 regulates the intrinsic excitability of cerebellar Purkinje neurons. Neurobiol Dis 2009; 33:81-88. PMID: 18930825
  2. Xu L, Zeng LH, Wong M. Impaired astrocyte gap junction coupling and potassium buffering in a mouse model of Tuberous Sclerosis Complex. Neurobiol Dis 2009; 34:291-299. PMID: 19385061
  3. Zeng LH, Rensing NR, Wong M. The mammalian target of rapamycin (mTOR) signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy. J Neurosci 2009; 29:6964-6972. PMID: 19474323

Wu

  1. Wilson, E.H., Harris, T.H., Mrass, P., John, B., Tait, E.D., Wu, G.F., Pepper, M., Wherry, E.J., Dzierzinkski, F., Roos, D., Haydon, P.G., Laufer, T.M., Weninger, W., Hunter, C.A. Behavior of parasite specific effector CD8+ T cells in the CNS and visualization of a kinesis-associated system of reticular fibers during infection Immunity. 2009 Feb 20; 30 (2): 300-11.

Yamada

  1. Shakkottai, VG, Xiao, M, Xu, L, Wong, M, Nerbonne, JM, Ornitz, DM, Yamada, KA: FGF14 Regulates the Intrinsic Excitability of Cerebellar Purkinje Neurons, Neurobiology of Disease, 2009, 33: 81-88.

Zazulia

  1. Zazulia AR, Videen TO, Powers WJ (2009) Transient focal increase in perihematomal glucose metabolism after acute human intracerebral hemorrhage. Stroke, 40:1638-43.
  2. Dhar R, Zazulia AR, Videen TO, Zipfel GJ, Derdeyn CP, Diringer MN (2009) Red blood cell transfusion increases cerebral oxygen delivery in anemic patients with subarachnoid hemorrhage, Stroke, 40:3039-44.
  3. Zazulia A (2009) Mild cognitive impairment, carotid disease, and revascularization. JAMA, 301
  4. Diringer MN, Powers WJ, Zazulia AR, Videen TO (2009) Hyperoxia and traumatic brain injury. J Neurosurgery, 110:607-11
  5. Powers WJ, Videen TO, Diringer M, Aiyagari V, Zazulia A. (2009) Autoregulation after ischaemic stroke, J Hypertens, Epub ahead of print.

Zempel

  1. Lawrence R, Mathur A, The Tich SN, Zempel J, Inder T, A Pilot Study of Continuous Limited-Channel aEEG in Term Infants with Encephalopathy J Pediatr. 2009 Feb 19. [Epub ahead of print]
  2. Larson-Prior LJ, Zempel JM, Nolan TS, Prior FW, Snyder AZ, Raichle ME. Cortical network functional connectivity in the descent to sleep Proc Natl Acad Sci U S A. 2009 Mar 2. [Epub ahead of print]